Skip to main content

Table 1 List of AD and CON cases used for this study

From: Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology

Cases used for Western blotting
A. Hippocampus
Case number Braak stage (NFT) Phase of Aβ deposits CERAD neuritic plaque score Sex Age PMD Pathological diagnosis
1 0 O 0 M 51 7.45 CON
2 1 B 0 M 85 7.05 CON
3 1 A 0 F 60 7.30 CON
4 2 O 0 F 81 5.30 CON
5 3 A 0 F 91 5.20 CON
6 4 C 2 F 91 6.05 AD
7 5 C 2 F 89 4.40 AD
8 5 C 2 M 81 NA AD
9 5 B 2 F 69 7.10 AD
10 6 C 3 F 69 5.30 AD
11 6 C 3 F 68 3.50 AD
12 6 C 3 F 67 5.50 AD
B. Temporal cortex
13 0 B 0 M 74 7.45 CON
14 0 O 0 M 66 7.45 CON
15 1 O 0 M 77 8.25 CON
16 1 B 0 M 71 5.45 CON
17 2 O 0 F 93 5.50 CON
18 2 A 0 F 85 4.40 CON
19 3 C 1 F 82 6.05 AD
20 4 C 2 M 64 6.00 AD
21 5 C 3 F 71 4.15 AD
22 6 C 3 M 65 8.50 AD
23 6 C 3 F 64 3.40 AD
24 6 C 3 M 69 5.30 AD
C. Cases used for immunohistochemistry
Case number Braak stage (NFT) Phase of Aβ deposits CERAD neuritic plaque score Sex Age PMD (hrs) Pathological diagnosis
*25 0 O 0 M 74 8.05 CON
26 1 O 0 F 75 5.25 CON
27 1 O 0 M 82 5.50 CON
28 1 B 0 F 85 7.05 CON
29 1 B 0 F 73 7.45 CON
30 1 O 0 F 60 6.50 CON
31 1 O 0 M 78 17.40 CON
32 2 B 0 F 84 6.05 CON
33 2 B 0 F 83 4.40 CON
34 5 C 2 F 84 4.50 AD
35 6 C 3 F 62 4.45 AD
*36 6 C 3 M 60 6.15 AD
37 6 C 3 F 82 5.30 AD
38 6 C 3 M 74 7.40 AD
39 6 C 3 F 81 6.00 AD
40 6 C 3 M 73 6.15 AD
41 6 C 3 M 74 5.35 AD
*42 6 C 3 F 82 6.00 AD
*43 6 C 3 F 67 6.05 AD
*44 5/6 NA NA M 76 24.00 AD, CAA type 2
*45 5 C 3 M 65 7.20 AD, CAA type 2
46 6 C 3 F 87 8.00 AD, CAA type 2
  1. CON control case, AD Alzheimer’s disease case, NFT neurofibrillary tangles, CERAD consortium to establish a registry for Alzheimer’s disease, PMD post mortem delay, hrs hours, CAA cerebral amyloid aniopathy, NA not available
  2. All cases were used for quantification (Figs. 1 and 3) except when indicated with *